Latest News & Features

Reset all filters
Article Type
Channels & Sectors

Refine Search
An LSPN panel discusses the challenges and strategies for effective collaboration between in-house counsel and outside legal teams, stressing the importance of communication, strategic planning, and clear expectations.   14 May 2024
New recruit, who joins the firm’s Orange County office, brings patent experience in genomics, immunology and gene editing technologies.   14 May 2024
As Congress considers the Patent Eligibility Restoration Act of 2023, experts from NeoGenomics, Biogen, and Choate Hall & Stewart at LSPN Spring weigh in on its potential effect and the need for further clarification to improve patent eligibility standards.   13 May 2024
A significant uptake in unitary patents show court is here “in a big way” | Speakers shed light on the UPC's approach to preliminary injunctions and evidence gathering at LSPN Spring in Boston.   9 May 2024
Unified Patent Court
10x Genomics injunction showed the need to take the court ‘really seriously’ says US lawyer | With a focus on efficiency and plaintiff-friendly measures, the UPC's impact on patent valuations and litigation strategies is becoming increasingly apparent, at LSPN Spring.   9 May 2024
Biotech firm to ask Munich court to permanently lift injunction on CosMx products following ruling | Judgment comes a day after acquisition by Bruker was finalised.   9 May 2024
Star litigator moves firms with nearly a dozen attorneys | Biologic drug patent and Hatch-Waxman patent expert David Hanna also joins.   7 May 2024
Big Pharma
Asthma is one of the most common respiratory diseases in the US and the most common chronic disease among children | Israeli pharma giant’s suit comes amid allegations that it keeps life-saving prescriptions treatments artificially high.   7 May 2024
Two-day event in Boston brings together leading in-house patent counsel | Regeneron, USPTO, the Broad Institute and Novartis among attendees I Agenda includes the UPC, patent strategies, and multijurisdictional patent litigation | Registrations for LSPN Fall now open.   7 May 2024
Big Pharma
AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in second wave of challenges by Federal Trade Commission | ‘Junk patents’ block competition and ramp up prices unfairly, says FTC chair.   2 May 2024